VCB-1201 / Vaxcell-Bio Therap - LARVOL DELTA

Vaxcellbio registers patent for BCMA nanobody-based 'CAR-MIL' [Google translation] (The Bio) - "The patent was jointly filed with the Chonnam National University R&BD Foundation (CNU R&BD Foundation) and China's Hebei Senlang Biotechnology. This patent builds upon the bone marrow infiltrating lymphocyte culture and activation patent registered on September 29."

Patent • Multiple Myeloma

Vaxcellbio wins grant for CAR-MIL as BMS, J&J face Korea roadblocks (Korea Biomedical Review) - "The company said Tuesday it secured a 24-month R&D grant from the Korea Drug Development Fund (KDDF) to advance VCB-1201, a CAR-MIL therapy for relapsed or refractory multiple myeloma. The funding will support preclinical studies through March 2027, with a clinical trial application expected to follow. The grant amount was not disclosed....The project is part of KDDF’s 2.17 trillion won ($1.5 billion) national initiative to fund more than 1,200 drug development efforts through 2030. The fund is prioritizing cell and gene therapies, oncology, and other 'high-potential areas' to help Korean companies bridge the gap between research and commercialization."

Financing • Multiple Myeloma

Vaxell Bio Announces Results of Preclinical Study of BCMA CAR-MILs at ICBMT [Google translation] (Hankyung) - "Vaxcell Biotechnology...announced for the first time the results of a mouse experiment for BCMA (B-cell maturation antigen) CAR-MILs, a multiple myeloma treatment using dual-target nanoantigen recognition technology, at the 8th International Conference of the Korean Society for Blood and Marrow Transplantation (ICBMT 2024) held at BEXCO in Busan from the 26th to the 28th....According to VaxcellBio, the mouse experimental group administered BCMA CAR-MILs showed higher tumor killing power and mouse survival rate than the four control groups (1. No manipulation group; 2. T cell administration group; 3. MILs administration group; 4. BCMA CAR-T administration group). In particular, the experimental group had significantly higher immune cell and cytokine concentrations than the BCMA CAR-T control group, which showed excellent cancer cell killing power and survival rate among the control groups, and as a result, the tumor size was suppressed the best, and the mouse survival..."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

VaxCell-Bio partners with ProBio to accelerate CAR-related therapies development (Korea Biomedical Review) - "VaxCell-Bio...said it signed a memorandum of understanding (MOU) with ProBio, a global contract development and manufacturing organization (CDMO), to accelerate the development of its chimeric antigen receptor (CAR)-related therapies...Under this agreement, the two companies will collaborate on the development, manufacturing, and clinical processes of CAR therapies in compliance with good manufacturing practices (GMP), with a focus on antibody drug development, gene and cell therapy-based drug discovery, and the creation of advanced pharmaceutical manufacturing processes....VaxCell-Bio is optimistic that its partnership with ProBio, a company with extensive experience in cell therapy development and commercialization, will provide a solid foundation for its ongoing projects, including dual-target CAR-T, CAR-MILs, and CAR-NK platform therapies."

Licensing / partnership • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Hepatocellular Cancer • Multiple Myeloma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Vaxcell Bio forms a scientific advisory group and launches an integrated R&D center [Google translation] (HIT News) - "Vaxcell Bio...launched a new scientific advisory group and integrated and expanded its research and development (R&D) organization...Vaxcell Bio signed a one-year advisory contract with new scientific advisory committee members, including Dr. Byeong-wook Ryu, who has led the research and development of CAR-T treatments in the United States, and Professor Seung-hwan Lee, a professor at the University of Ottawa in Canada, who is considered an authority on immune cell therapy research and development. It was announced on the 14th that it was done....'With the joining of the two scientists, the research and development of CAR-T, CAR-NK, and CAR-MILs, the Vax-CAR platform built by Vaxcell Bio, will accelerate and will have the effect of being recognized externally.'"

Licensing / partnership • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor

VaxCell-Bio becomes 1st Korean firm to submit patent for CAR-MILs multiple myeloma treatment in Europe, China (Korea Biomedical Review) - "VaxCell-Bio said it submitted an international patent for a new multiple myeloma treatment known as chimeric-antigen receptor-marrow-infiltrating lymphocytes (CAR-MILs) in Europe and China. The submission marks a significant step becasue it is the first time a Korean firm has sought international patent protection for the novel CAR-MILs candidate, the Kosdaq-listed company said. Following its initial patent application in Korea in January, VaxCell-Bio had been planning to extend its patent filings to Europe, China, and other countries as it aims to establish a global presence in the multiple myeloma treatment market. The innovative CAR-MILs therapy, developed by VaxCell-Bio, involves the extraction of MILs from the bone marrow of multiple myeloma patients."

Patent • Multiple Myeloma

Vaxcell Bio continues development of CAR-MILs… Multiple myeloma treatment patent application [Google translation] (eDaily) - "Vaxcell Bio announced on the 26th that it has applied for a patent for CAR-MILs multiple myeloma treatment made by attaching chimeric antigen receptor (CAR) to immune cells extracted from the bone marrow of multiple myeloma patients....Vaxcell Bio is the only company known to be developing a CAR-MILs treatment in Korea, and no CAR-MILs products have yet been released globally."

Patent • Hematological Malignancies • Multiple Myeloma • Oncology